泽璟制药：注射用ZG005、注射用ZGGS18与盐酸吉卡昔替尼片联合用于晚期实体瘤的临床试验获批

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its innovative cancer immunotherapy products, ZG005 and ZGGS18, in combination with a specific drug for advanced solid tumors [1] Group 1: Product Information - ZG005 is a recombinant humanized anti-PD-1/TIGIT bispecific antibody classified as a Class 1 innovative tumor immunotherapy biological product [1] - ZG005 is among the first drugs globally to enter clinical research targeting the same mechanism, with no similar mechanism drugs approved for market worldwide [1] Group 2: Clinical Trial Approval - The clinical trial approval includes the use of ZG005 and ZGGS18 in conjunction with hydrochloride gicaxetine tablets for advanced solid tumors [1]